Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Vortioxetine in Healthy Chinese Subjects
NCT02386488Phase 1Completed
- Sponsor
- Lundbeck
- Start
- Mar 2015
- Primary completion
- May 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of vortioxetine in major depressive disorder (MDD) (4 arms), sponsored by Lundbeck. Primary endpoint: Pharmacokinetics of vortioxetine and its metabolites. Started Mar 2015; status: completed.
02
Drugs
vortioxetine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT02386488.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02386488.